NICE rejects BMS’ Zeposia MS pill in provisional guidanceNICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing Share XNICE rejects BMS’ Zeposia MS pill in provisional guidancehttps://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
BMS/Celgene merger payout evaporates as CVR deadline passesFormer Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three Share XBMS/Celgene merger payout evaporates as CVR deadline passeshttps://pharmaphorum.com/news/bms-celgene-merger-payout-evaporates-as-cvr-deadline-passes/
BMS calls time on brain cancer trial as Opdivo misses second targetBristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of Share XBMS calls time on brain cancer trial as Opdivo misses second targethttps://pharmaphorum.com/news/bms-calls-time-on-brain-cancer-trial-as-opdivo-misses-second-target/
Fresh doubts over BMS’ merger payout as FDA delays key drug reviewHolders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out Share XFresh doubts over BMS’ merger payout as FDA delays key drug reviewhttps://pharmaphorum.com/news/fresh-doubts-over-bms-merger-payout-as-fda-delays-key-drug-review/
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor Share XCould an FDA inspection scupper CVR deadline for BMS’ liso-cel?https://pharmaphorum.com/news/could-an-fda-inspection-scupper-cvr-deadline-for-bms-liso-cel/
BMS’ deucravacitinib psoriasis pill outperforms Amgen’s Otezla in phase 3Bristol-Myers Squibb could be on the verge of a major coup in psoriasis after its deucravacitinib pill outperformed Share XBMS’ deucravacitinib psoriasis pill outperforms Amgen’s Otezla in phase 3https://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-outperforms-amgens-otezla-in-phase-3/
BMS joins forces with insitro to develop neurodegenerative treatmentsinsitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies Share XBMS joins forces with insitro to develop neurodegenerative treatmentshttps://pharmaphorum.com/news/bms-joins-forces-with-insitro-to-develop-neurodegenerative-treatments/
FDA kicks off review of second kidney cancer combo based on BMS’ OpdivoBristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy Share XFDA kicks off review of second kidney cancer combo based on BMS’ Opdivohttps://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/
